Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Damora Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 25 | 23 | −2 |
| Shares | 9.57M | 9.10M | −462.3K (−4.8%) |
| Value | $21.0M | $15.7M | −$5.30M (−25.2%) |
New holders (2)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MAI Capital Management | 320,860 | $555.0K | 0.01% |
| Curi Capital | 76 | $0 | 0.00% |
Sold out (4)
Institutions that held Damora Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Janus Henderson Group PLC | 724,523 | $1.59M |
| UBS Group AG | 2,495 | $5.00K |
| Citigroup Inc | 242 | $1.00K |
| Morgan Stanley | 563 | $1.00K |